doi: 10.1016/0165-0327(95)00028-L 246 CatapanoALPirilloABonacinaFNorataGD
doi: 10.1111/bph.v176.17 82 LiPMaoLZhouGLeakRKSunBLChenJet al
Compounded by Optimal Balance Pharmacy under a 503A patient-specific prescription
[] Furthermore, because of DFOs principal limitation as a therapeutic agent being limited by its mode of administration, which is primarily parenteral and the associated issues related to its administration, much research is still needed to develop DFO derivatives with greater therapeutic potentialities
PubMed, Zhou, Dongchen, et al
108 Further research has shown that BACH1 inhibits the Nrf2 pathway by binding to Nrf2, and promotes the increase of labile iron in PDAC cells, leading to ferroptosis